Browsing Tag
geographic atrophy
8 posts
Can Ocugen, Inc. disrupt chronic eye injections with a single gene therapy procedure? (NASDAQ: OCGN)
Ocugen, Inc. reports Phase 2 gene therapy results that could reshape retinal treatment economics. Discover what this means for investors and competitors.
Positive early Phase 2 data strengthen Ocugen’s case for OCU410 in the fast-evolving dry AMD treatment market
Find out how Ocugen’s early Phase 2 data for OCU410 could reshape competition and investor sentiment in the fast-growing dry AMD treatment market.
Emmecell names ex-AbbVie executive Ramin Valian as CEO to lead cell therapy platform
Emmecell names Ramin Valian as CEO to guide its magnetic cell delivery platform toward pivotal trials. Find out what this leadership shift means for the industry.
Emmecell taps AbbVie veteran Ramin Valian as CEO to lead magnetic cell therapy into pivotal trials
Emmecell has named former AbbVie executive Ramin Valian as CEO to lead its magnetic cell therapy platform into pivotal trials. Find out what this signals next.
Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy
Ocugen, Inc. has taken a significant step forward in the fight against geographic atrophy (GA) secondary to dry…
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around…
Apellis to submit NDA for intravitreal pegcetacoplan to FDA in H1 2022
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal…
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy,…